CareMax, Inc. (CMAX) Stock Competitors & Peer Comparison
See (CMAX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CMAX | $0.42 | +0.00% | 1.6M | -0.00 | -$208.91 | N/A |
| GEHC | $65.76 | +1.26% | 29.9B | 14.42 | $4.56 | +0.21% |
| VEEV | $171.36 | +8.40% | 27.8B | 20.56 | $8.33 | N/A |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSGU | $227.96 | -0.94% | 13.9B | 206.12 | $1.11 | N/A |
| BTSG | $68.98 | -1.03% | 13.5B | 55.52 | $1.24 | N/A |
| TEM | $56.14 | +2.31% | 9.8B | -39.93 | -$1.41 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $88.46 | +6.03% | 7.4B | 20.67 | $4.28 | N/A |
| HNGE | $78.97 | +5.10% | 6.1B | 40.46 | $1.95 | N/A |
Stock Comparison
CMAX vs GEHC Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, GEHC has a market cap of 29.9B. Regarding current trading prices, CMAX is priced at $0.42, while GEHC trades at $65.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas GEHC's P/E ratio is 14.42. In terms of profitability, CMAX's ROE is -2.01%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, CMAX is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check GEHC's competition here
CMAX vs VEEV Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, VEEV has a market cap of 27.8B. Regarding current trading prices, CMAX is priced at $0.42, while VEEV trades at $171.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas VEEV's P/E ratio is 20.56. In terms of profitability, CMAX's ROE is -2.01%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, CMAX is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check VEEV's competition here
CMAX vs GEHCV Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, CMAX is priced at $0.42, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas GEHCV's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, CMAX is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check GEHCV's competition here
CMAX vs BTSGU Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, BTSGU has a market cap of 13.9B. Regarding current trading prices, CMAX is priced at $0.42, while BTSGU trades at $227.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas BTSGU's P/E ratio is 206.12. In terms of profitability, CMAX's ROE is -2.01%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, CMAX is less volatile compared to BTSGU. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check BTSGU's competition here
CMAX vs BTSG Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, BTSG has a market cap of 13.5B. Regarding current trading prices, CMAX is priced at $0.42, while BTSG trades at $68.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas BTSG's P/E ratio is 55.52. In terms of profitability, CMAX's ROE is -2.01%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, CMAX is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check BTSG's competition here
CMAX vs TEM Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, TEM has a market cap of 9.8B. Regarding current trading prices, CMAX is priced at $0.42, while TEM trades at $56.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas TEM's P/E ratio is -39.93. In terms of profitability, CMAX's ROE is -2.01%, compared to TEM's ROE of -0.70%. Regarding short-term risk, CMAX is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check TEM's competition here
CMAX vs SGFY Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, CMAX is priced at $0.42, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SGFY's P/E ratio is 70.91. In terms of profitability, CMAX's ROE is -2.01%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, CMAX is less volatile compared to SGFY. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SGFY's competition here
CMAX vs HQY Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, HQY has a market cap of 7.4B. Regarding current trading prices, CMAX is priced at $0.42, while HQY trades at $88.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas HQY's P/E ratio is 20.67. In terms of profitability, CMAX's ROE is -2.01%, compared to HQY's ROE of +0.11%. Regarding short-term risk, CMAX is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check HQY's competition here
CMAX vs HNGE Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, HNGE has a market cap of 6.1B. Regarding current trading prices, CMAX is priced at $0.42, while HNGE trades at $78.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas HNGE's P/E ratio is 40.46. In terms of profitability, CMAX's ROE is -2.01%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, CMAX is less volatile compared to HNGE. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check HNGE's competition here
CMAX vs RCM Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, CMAX is priced at $0.42, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas RCM's P/E ratio is -102.21. In terms of profitability, CMAX's ROE is -2.01%, compared to RCM's ROE of +0.00%. Regarding short-term risk, CMAX and RCM have similar daily volatility (0.00).Check RCM's competition here
CMAX vs TXG Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, TXG has a market cap of 4.7B. Regarding current trading prices, CMAX is priced at $0.42, while TXG trades at $36.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas TXG's P/E ratio is -216.18. In terms of profitability, CMAX's ROE is -2.01%, compared to TXG's ROE of -0.03%. Regarding short-term risk, CMAX is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check TXG's competition here
CMAX vs DOCS Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, DOCS has a market cap of 3.9B. Regarding current trading prices, CMAX is priced at $0.42, while DOCS trades at $20.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas DOCS's P/E ratio is 13.64. In terms of profitability, CMAX's ROE is -2.01%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, CMAX is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check DOCS's competition here
CMAX vs ONEM Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, CMAX is priced at $0.42, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ONEM's P/E ratio is -7.77. In terms of profitability, CMAX's ROE is -2.01%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, CMAX is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check ONEM's competition here
CMAX vs PRVA Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, PRVA has a market cap of 3.2B. Regarding current trading prices, CMAX is priced at $0.42, while PRVA trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas PRVA's P/E ratio is 159.81. In terms of profitability, CMAX's ROE is -2.01%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, CMAX is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check PRVA's competition here
CMAX vs HTFL Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, HTFL has a market cap of 3.1B. Regarding current trading prices, CMAX is priced at $0.42, while HTFL trades at $35.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas HTFL's P/E ratio is -17.74. In terms of profitability, CMAX's ROE is -2.01%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, CMAX is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check HTFL's competition here
CMAX vs PINC Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, CMAX is priced at $0.42, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas PINC's P/E ratio is 166.24. In terms of profitability, CMAX's ROE is -2.01%, compared to PINC's ROE of -0.02%. Regarding short-term risk, CMAX and PINC have similar daily volatility (0.00).Check PINC's competition here
CMAX vs PGNY Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, PGNY has a market cap of 2.2B. Regarding current trading prices, CMAX is priced at $0.42, while PGNY trades at $28.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas PGNY's P/E ratio is 20.81. In terms of profitability, CMAX's ROE is -2.01%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, CMAX is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check PGNY's competition here
CMAX vs WGS Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, WGS has a market cap of 2.1B. Regarding current trading prices, CMAX is priced at $0.42, while WGS trades at $69.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas WGS's P/E ratio is 82.14. In terms of profitability, CMAX's ROE is -2.01%, compared to WGS's ROE of -0.28%. Regarding short-term risk, CMAX is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check WGS's competition here
CMAX vs WGSWW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, WGSWW has a market cap of 1.6B. Regarding current trading prices, CMAX is priced at $0.42, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas WGSWW's P/E ratio is -0.10. In terms of profitability, CMAX's ROE is -2.01%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, CMAX is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check WGSWW's competition here
CMAX vs NXGN Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, CMAX is priced at $0.42, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas NXGN's P/E ratio is -266.00. In terms of profitability, CMAX's ROE is -2.01%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, CMAX is less volatile compared to NXGN. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check NXGN's competition here
CMAX vs TDOC Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, TDOC has a market cap of 1.5B. Regarding current trading prices, CMAX is priced at $0.42, while TDOC trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas TDOC's P/E ratio is -9.31. In terms of profitability, CMAX's ROE is -2.01%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, CMAX is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check TDOC's competition here
CMAX vs AGTI Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, CMAX is priced at $0.42, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas AGTI's P/E ratio is -71.79. In terms of profitability, CMAX's ROE is -2.01%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, CMAX is less volatile compared to AGTI. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check AGTI's competition here
CMAX vs OMDA Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, OMDA has a market cap of 1.2B. Regarding current trading prices, CMAX is priced at $0.42, while OMDA trades at $20.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas OMDA's P/E ratio is 298.43. In terms of profitability, CMAX's ROE is -2.01%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, CMAX is less volatile compared to OMDA. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check OMDA's competition here
CMAX vs NUTX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, NUTX has a market cap of 990.8M. Regarding current trading prices, CMAX is priced at $0.42, while NUTX trades at $166.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas NUTX's P/E ratio is 12.86. In terms of profitability, CMAX's ROE is -2.01%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, CMAX is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check NUTX's competition here
CMAX vs GDRX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, GDRX has a market cap of 970.6M. Regarding current trading prices, CMAX is priced at $0.42, while GDRX trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas GDRX's P/E ratio is 8.48. In terms of profitability, CMAX's ROE is -2.01%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, CMAX is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check GDRX's competition here
CMAX vs CERT Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CERT has a market cap of 908.5M. Regarding current trading prices, CMAX is priced at $0.42, while CERT trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CERT's P/E ratio is 14.97. In terms of profitability, CMAX's ROE is -2.01%, compared to CERT's ROE of -0.01%. Regarding short-term risk, CMAX is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CERT's competition here
CMAX vs CCLDO Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, CMAX is priced at $0.42, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CCLDO's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, CMAX and CCLDO have similar daily volatility (0.00).Check CCLDO's competition here
CMAX vs HSTM Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, HSTM has a market cap of 780.9M. Regarding current trading prices, CMAX is priced at $0.42, while HSTM trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas HSTM's P/E ratio is 35.17. In terms of profitability, CMAX's ROE is -2.01%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, CMAX is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check HSTM's competition here
CMAX vs MPLN-WT Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, CMAX is priced at $0.42, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, CMAX is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check MPLN-WT's competition here
CMAX vs PHR Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, PHR has a market cap of 618.7M. Regarding current trading prices, CMAX is priced at $0.42, while PHR trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas PHR's P/E ratio is 35.75. In terms of profitability, CMAX's ROE is -2.01%, compared to PHR's ROE of +0.03%. Regarding short-term risk, CMAX is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check PHR's competition here
CMAX vs EVH Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, EVH has a market cap of 613.6M. Regarding current trading prices, CMAX is priced at $0.42, while EVH trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas EVH's P/E ratio is 545.50. In terms of profitability, CMAX's ROE is -2.01%, compared to EVH's ROE of -0.78%. Regarding short-term risk, CMAX is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check EVH's competition here
CMAX vs ACCD Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, CMAX is priced at $0.42, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ACCD's P/E ratio is -3.08. In terms of profitability, CMAX's ROE is -2.01%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, CMAX and ACCD have similar daily volatility (0.00).Check ACCD's competition here
CMAX vs CCLDP Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, CMAX is priced at $0.42, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CCLDP's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, CMAX is less volatile compared to CCLDP. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CCLDP's competition here
CMAX vs CTEV Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CTEV has a market cap of 565.3M. Regarding current trading prices, CMAX is priced at $0.42, while CTEV trades at $33.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CTEV's P/E ratio is -2.54. In terms of profitability, CMAX's ROE is -2.01%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, CMAX is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CTEV's competition here
CMAX vs SHCR Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, CMAX is priced at $0.42, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SHCR's P/E ratio is -3.76. In terms of profitability, CMAX's ROE is -2.01%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, CMAX is less volatile compared to SHCR. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SHCR's competition here
CMAX vs NRC Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, NRC has a market cap of 469M. Regarding current trading prices, CMAX is priced at $0.42, while NRC trades at $20.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas NRC's P/E ratio is 23.65. In terms of profitability, CMAX's ROE is -2.01%, compared to NRC's ROE of +0.57%. Regarding short-term risk, CMAX is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check NRC's competition here
CMAX vs SOPH Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SOPH has a market cap of 412.1M. Regarding current trading prices, CMAX is priced at $0.42, while SOPH trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SOPH's P/E ratio is -11.06. In terms of profitability, CMAX's ROE is -2.01%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, CMAX is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SOPH's competition here
CMAX vs SLGC Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, CMAX is priced at $0.42, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SLGC's P/E ratio is -3.04. In terms of profitability, CMAX's ROE is -2.01%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, CMAX is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SLGC's competition here
CMAX vs SLGCW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, CMAX is priced at $0.42, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, CMAX's ROE is -2.01%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, CMAX is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SLGCW's competition here
CMAX vs TBRG Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, TBRG has a market cap of 393M. Regarding current trading prices, CMAX is priced at $0.42, while TBRG trades at $26.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas TBRG's P/E ratio is 9.36. In terms of profitability, CMAX's ROE is -2.01%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, CMAX is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check TBRG's competition here
CMAX vs MPLN Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, CMAX is priced at $0.42, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas MPLN's P/E ratio is -0.23. In terms of profitability, CMAX's ROE is -2.01%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, CMAX is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check MPLN's competition here
CMAX vs SLP Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SLP has a market cap of 367.7M. Regarding current trading prices, CMAX is priced at $0.42, while SLP trades at $18.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SLP's P/E ratio is 17.67. In terms of profitability, CMAX's ROE is -2.01%, compared to SLP's ROE of -0.49%. Regarding short-term risk, CMAX is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SLP's competition here
CMAX vs TRHC Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, CMAX is priced at $0.42, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas TRHC's P/E ratio is -4.27. In terms of profitability, CMAX's ROE is -2.01%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, CMAX is less volatile compared to TRHC. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check TRHC's competition here
CMAX vs SMFR Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, CMAX is priced at $0.42, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SMFR's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, CMAX is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SMFR's competition here
CMAX vs SPOK Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SPOK has a market cap of 222.4M. Regarding current trading prices, CMAX is priced at $0.42, while SPOK trades at $10.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SPOK's P/E ratio is 17.75. In terms of profitability, CMAX's ROE is -2.01%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, CMAX is less volatile compared to SPOK. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SPOK's competition here
CMAX vs SY Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SY has a market cap of 186.3M. Regarding current trading prices, CMAX is priced at $0.42, while SY trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SY's P/E ratio is -4.30. In terms of profitability, CMAX's ROE is -2.01%, compared to SY's ROE of -0.16%. Regarding short-term risk, CMAX is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SY's competition here
CMAX vs AMWL Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, AMWL has a market cap of 150.4M. Regarding current trading prices, CMAX is priced at $0.42, while AMWL trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas AMWL's P/E ratio is -1.73. In terms of profitability, CMAX's ROE is -2.01%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, CMAX is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check AMWL's competition here
CMAX vs HCAT Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, HCAT has a market cap of 140.4M. Regarding current trading prices, CMAX is priced at $0.42, while HCAT trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas HCAT's P/E ratio is 9.50. In terms of profitability, CMAX's ROE is -2.01%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, CMAX is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check HCAT's competition here
CMAX vs CPSI Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, CMAX is priced at $0.42, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CPSI's P/E ratio is -183.80. In terms of profitability, CMAX's ROE is -2.01%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, CMAX is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CPSI's competition here
CMAX vs AUGX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, CMAX is priced at $0.42, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas AUGX's P/E ratio is -4.99. In terms of profitability, CMAX's ROE is -2.01%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, CMAX is less volatile compared to AUGX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check AUGX's competition here
CMAX vs OPRX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, OPRX has a market cap of 96.1M. Regarding current trading prices, CMAX is priced at $0.42, while OPRX trades at $5.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas OPRX's P/E ratio is 4.70. In terms of profitability, CMAX's ROE is -2.01%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, CMAX is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check OPRX's competition here
CMAX vs CCLD Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CCLD has a market cap of 91.4M. Regarding current trading prices, CMAX is priced at $0.42, while CCLD trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CCLD's P/E ratio is 6.52. In terms of profitability, CMAX's ROE is -2.01%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, CMAX is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CCLD's competition here
CMAX vs DH Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, DH has a market cap of 69.6M. Regarding current trading prices, CMAX is priced at $0.42, while DH trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas DH's P/E ratio is 2.54. In terms of profitability, CMAX's ROE is -2.01%, compared to DH's ROE of -0.67%. Regarding short-term risk, CMAX is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check DH's competition here
CMAX vs FORA Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, CMAX is priced at $0.42, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas FORA's P/E ratio is -24.11. In terms of profitability, CMAX's ROE is -2.01%, compared to FORA's ROE of -0.17%. Regarding short-term risk, CMAX and FORA have similar daily volatility (0.00).Check FORA's competition here
CMAX vs ONMD Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ONMD has a market cap of 35.9M. Regarding current trading prices, CMAX is priced at $0.42, while ONMD trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ONMD's P/E ratio is -4.40. In terms of profitability, CMAX's ROE is -2.01%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, CMAX is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check ONMD's competition here
CMAX vs SNCE Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, CMAX is priced at $0.42, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SNCE's P/E ratio is -0.27. In terms of profitability, CMAX's ROE is -2.01%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, CMAX is less volatile compared to SNCE. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SNCE's competition here
CMAX vs AKLI Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, CMAX is priced at $0.42, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas AKLI's P/E ratio is -0.71. In terms of profitability, CMAX's ROE is -2.01%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, CMAX is less volatile compared to AKLI. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check AKLI's competition here
CMAX vs SHLT Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, CMAX is priced at $0.42, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SHLT's P/E ratio is -3.87. In terms of profitability, CMAX's ROE is -2.01%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, CMAX and SHLT have similar daily volatility (0.00).Check SHLT's competition here
CMAX vs ONMDW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ONMDW has a market cap of 33.2M. Regarding current trading prices, CMAX is priced at $0.42, while ONMDW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ONMDW's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, CMAX is less volatile compared to ONMDW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check ONMDW's competition here
CMAX vs SHCRW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, CMAX is priced at $0.42, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, CMAX's ROE is -2.01%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, CMAX is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SHCRW's competition here
CMAX vs EUDA Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, EUDA has a market cap of 28.4M. Regarding current trading prices, CMAX is priced at $0.42, while EUDA trades at $15.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas EUDA's P/E ratio is -2.79. In terms of profitability, CMAX's ROE is -2.01%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, CMAX is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check EUDA's competition here
CMAX vs STRM Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, CMAX is priced at $0.42, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas STRM's P/E ratio is -2.40. In terms of profitability, CMAX's ROE is -2.01%, compared to STRM's ROE of -0.32%. Regarding short-term risk, CMAX and STRM have similar daily volatility (0.00).Check STRM's competition here
CMAX vs RNLX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, CMAX is priced at $0.42, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas RNLX's P/E ratio is -0.33. In terms of profitability, CMAX's ROE is -2.01%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, CMAX is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check RNLX's competition here
CMAX vs LIFW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, CMAX is priced at $0.42, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas LIFW's P/E ratio is -0.02. In terms of profitability, CMAX's ROE is -2.01%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, CMAX and LIFW have similar daily volatility (0.00).Check LIFW's competition here
CMAX vs BEATW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, BEATW has a market cap of 17.3M. Regarding current trading prices, CMAX is priced at $0.42, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas BEATW's P/E ratio is -0.05. In terms of profitability, CMAX's ROE is -2.01%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, CMAX and BEATW have similar daily volatility (0.00).Check BEATW's competition here
CMAX vs BBLN Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, CMAX is priced at $0.42, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas BBLN's P/E ratio is -0.04. In terms of profitability, CMAX's ROE is -2.01%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, CMAX is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check BBLN's competition here
CMAX vs ETAO Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, CMAX is priced at $0.42, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ETAO's P/E ratio is -0.01. In terms of profitability, CMAX's ROE is -2.01%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, CMAX is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check ETAO's competition here
CMAX vs BFRG Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, BFRG has a market cap of 7.6M. Regarding current trading prices, CMAX is priced at $0.42, while BFRG trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas BFRG's P/E ratio is -1.21. In terms of profitability, CMAX's ROE is -2.01%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, CMAX is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check BFRG's competition here
CMAX vs HLTH Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, CMAX is priced at $0.42, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas HLTH's P/E ratio is -0.02. In terms of profitability, CMAX's ROE is -2.01%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, CMAX is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check HLTH's competition here
CMAX vs SCNX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, SCNX has a market cap of 5.6M. Regarding current trading prices, CMAX is priced at $0.42, while SCNX trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas SCNX's P/E ratio is -0.14. In terms of profitability, CMAX's ROE is -2.01%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, CMAX is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check SCNX's competition here
CMAX vs UPH Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, CMAX is priced at $0.42, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas UPH's P/E ratio is -0.07. In terms of profitability, CMAX's ROE is -2.01%, compared to UPH's ROE of -1.05%. Regarding short-term risk, CMAX is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check UPH's competition here
CMAX vs UPH-WT Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, CMAX is priced at $0.42, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, CMAX is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check UPH-WT's competition here
CMAX vs PEARW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, CMAX is priced at $0.42, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas PEARW's P/E ratio is -0.00. In terms of profitability, CMAX's ROE is -2.01%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, CMAX is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check PEARW's competition here
CMAX vs PEAR Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, CMAX is priced at $0.42, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas PEAR's P/E ratio is -0.08. In terms of profitability, CMAX's ROE is -2.01%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, CMAX is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check PEAR's competition here
CMAX vs MGRX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, MGRX has a market cap of 3.7M. Regarding current trading prices, CMAX is priced at $0.42, while MGRX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas MGRX's P/E ratio is -0.27. In terms of profitability, CMAX's ROE is -2.01%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, CMAX is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check MGRX's competition here
CMAX vs HCTI Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, HCTI has a market cap of 2.4M. Regarding current trading prices, CMAX is priced at $0.42, while HCTI trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas HCTI's P/E ratio is -0.02. In terms of profitability, CMAX's ROE is -2.01%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, CMAX is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check HCTI's competition here
CMAX vs OTRK Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, CMAX is priced at $0.42, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas OTRK's P/E ratio is -0.02. In terms of profitability, CMAX's ROE is -2.01%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, CMAX and OTRK have similar daily volatility (0.00).Check OTRK's competition here
CMAX vs VSEEW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, VSEEW has a market cap of 1.9M. Regarding current trading prices, CMAX is priced at $0.42, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas VSEEW's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, CMAX and VSEEW have similar daily volatility (0.00).Check VSEEW's competition here
CMAX vs VSEE Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, VSEE has a market cap of 1.8M. Regarding current trading prices, CMAX is priced at $0.42, while VSEE trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas VSEE's P/E ratio is -0.21. In terms of profitability, CMAX's ROE is -2.01%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, CMAX is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check VSEE's competition here
CMAX vs BFRGW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, BFRGW has a market cap of 1.6M. Regarding current trading prices, CMAX is priced at $0.42, while BFRGW trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas BFRGW's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, CMAX is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check BFRGW's competition here
CMAX vs ACON Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ACON has a market cap of 1.5M. Regarding current trading prices, CMAX is priced at $0.42, while ACON trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ACON's P/E ratio is -0.26. In terms of profitability, CMAX's ROE is -2.01%, compared to ACON's ROE of -0.54%. Regarding short-term risk, CMAX is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check ACON's competition here
CMAX vs LIFWZ Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, CMAX is priced at $0.42, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, CMAX and LIFWZ have similar daily volatility (0.00).Check LIFWZ's competition here
CMAX vs EUDAW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, EUDAW has a market cap of 869.6K. Regarding current trading prices, CMAX is priced at $0.42, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, CMAX's ROE is -2.01%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, CMAX is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check EUDAW's competition here
CMAX vs MSPRZ Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, CMAX is priced at $0.42, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, CMAX is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check MSPRZ's competition here
CMAX vs WORX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, CMAX is priced at $0.42, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas WORX's P/E ratio is -1.17. In terms of profitability, CMAX's ROE is -2.01%, compared to WORX's ROE of -0.65%. Regarding short-term risk, CMAX is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check WORX's competition here
CMAX vs KERNW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, CMAX is priced at $0.42, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas KERNW's P/E ratio is -0.00. In terms of profitability, CMAX's ROE is -2.01%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, CMAX is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check KERNW's competition here
CMAX vs KERN Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, CMAX is priced at $0.42, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas KERN's P/E ratio is -0.01. In terms of profitability, CMAX's ROE is -2.01%, compared to KERN's ROE of -0.17%. Regarding short-term risk, CMAX is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check KERN's competition here
CMAX vs LIFWW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, CMAX is priced at $0.42, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas LIFWW's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, CMAX and LIFWW have similar daily volatility (0.00).Check LIFWW's competition here
CMAX vs CMAXW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, CMAX is priced at $0.42, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CMAXW's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, CMAX and CMAXW have similar daily volatility (0.00).Check CMAXW's competition here
CMAX vs ZCMD Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ZCMD has a market cap of 32.5K. Regarding current trading prices, CMAX is priced at $0.42, while ZCMD trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ZCMD's P/E ratio is -0.01. In terms of profitability, CMAX's ROE is -2.01%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, CMAX is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check ZCMD's competition here
CMAX vs ACONW Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, ACONW has a market cap of 14.4K. Regarding current trading prices, CMAX is priced at $0.42, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas ACONW's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, CMAX is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check ACONW's competition here
CMAX vs NAVA Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas NAVA's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, Volatility data is not available for a full comparison. CMAX has daily volatility of 0.00 and NAVA has daily volatility of N/A.Check NAVA's competition here
CMAX vs AFFX Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas AFFX's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, CMAX is less volatile compared to AFFX. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check AFFX's competition here
CMAX vs CHNGU Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CHNGU's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, CMAX is less volatile compared to CHNGU. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CHNGU's competition here
CMAX vs MTBC Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas MTBC's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, CMAX is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check MTBC's competition here
CMAX vs CERN Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CERN has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CERN's P/E ratio is 55.84. In terms of profitability, CMAX's ROE is -2.01%, compared to CERN's ROE of +0.14%. Regarding short-term risk, CMAX is less volatile compared to CERN. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CERN's competition here
CMAX vs CHNG Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CHNG's P/E ratio is -152.72. In terms of profitability, CMAX's ROE is -2.01%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, CMAX is less volatile compared to CHNG. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CHNG's competition here
CMAX vs CNVY Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas CNVY's P/E ratio is -71.50. In terms of profitability, CMAX's ROE is -2.01%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, CMAX is less volatile compared to CNVY. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check CNVY's competition here
CMAX vs KURIU Comparison July 2026
CMAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CMAX stands at 1.6M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, CMAX is priced at $0.42, while KURIU trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CMAX currently has a P/E ratio of -0.00, whereas KURIU's P/E ratio is N/A. In terms of profitability, CMAX's ROE is -2.01%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, CMAX is less volatile compared to KURIU. This indicates potentially lower risk in terms of short-term price fluctuations for CMAX.Check KURIU's competition here